DSG3-CAART Cell Therapy for Pemphigus Vulgaris
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing new cell therapies for patients with pemphigus vulgaris who don't respond to standard treatments. The therapies involve modifying the patient's own immune cells to better fight the disease and potentially provide long-term relief.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it excludes those who have taken certain treatments like rituximab in the last 12 months or investigational treatments in the last 3 months. It's best to discuss your specific medications with the trial team.
What safety data exists for DSG3-CAART cell therapy in humans?
How is DSG3-CAART treatment different from other treatments for pemphigus vulgaris?
What data supports the effectiveness of the treatment DSG3-CAART for pemphigus vulgaris?
Who Is on the Research Team?
Cabaletta Bio
Principal Investigator
Cabaletta Bio
Are You a Good Fit for This Trial?
This trial is for patients with mucosal-dominant pemphigus vulgaris (mPV) who haven't responded well to standard treatments. They must have active mPV symptoms, a positive anti-DSG3 antibody test, and a confirmed diagnosis. People can't join if they've had certain other treatments recently or have another autoimmune disease needing treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive fractionated infusions of DSG3-CAART or a single infusion of CABA-201
Follow-up
Participants are monitored for safety, clinical remission, and serologic remission
Extension
Long-term monitoring of pharmacodynamics and pharmacokinetics for CABA-201 sub-study
What Are the Treatments Tested in This Trial?
Interventions
- DSG3-CAART
DSG3-CAART is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cabaletta Bio
Lead Sponsor